Michael Allison
NIHR Cambridge Biomedical Research Centre · 167 works · 14,671 citations · h-index 49
Top works
- C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
- Observations on the ex situ perfusion of livers for transplantation
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
- Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
- Community attitudes to cystic fibrosis carrier testing in England: A pilot study
- Self‐renewal of B‐1 lymphocytes is dependent on CD19
- The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
- Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
- Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study
- Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
- Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK
- Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease
- In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA
- Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease